This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: Mannkind Corporation. Active years: 2005-2013.
Company Filing History:
Years Active: 2005-2013
Title: Thomas M Kündig: Innovator in Immunological Responses
Introduction
Thomas M Kündig is a prominent inventor based in Zurich, Switzerland. He has made significant contributions to the field of immunology, particularly in the development of methods for inducing cytotoxic T lymphocyte (CTL) responses. With a total of 4 patents to his name, his work has the potential to impact therapeutic strategies in immunology.
Latest Patents
Kündig's latest patents focus on innovative methods for inducing an immunological CTL response to antigens. These methods involve the sustained and regular delivery of antigens to mammals, ensuring that the antigens reach the lymphatic system. The delivery is designed to maintain a sufficient level of the antigen over time, which is crucial for sustaining the immunologic CTL response. Additionally, he has developed an article of manufacture aimed at delivering antigens that can effectively induce a CTL response in animals.
Career Highlights
Throughout his career, Thomas M Kündig has been associated with Mannkind Corporation, where he has been able to apply his expertise in immunology. His work has garnered attention for its innovative approach to enhancing immune responses, which is vital for developing new therapeutic interventions.
Collaborations
Kündig has collaborated with notable colleagues, including John J L Simard and John L Simard. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Thomas M Kündig stands out as an influential inventor in the field of immunology, with a focus on methods that enhance CTL responses. His contributions through his patents and collaborations continue to pave the way for advancements in immunological therapies.